AN INTEGRATED PERSPECTIVE ON POTENTIAL RISK FACTORS FOR MENINGIOMA DEVELOPMENT: A REVIEW

Olha Levchenko; Rafał Kobylański; Katarzyna Nycz

doi:10.31435/ijitss.2(50).2026.5238

Authors

Olha Levchenko Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland https://orcid.org/0009-0006-8743-3598
Rafał Kobylański Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland https://orcid.org/0009-0005-9221-1247
Katarzyna Nycz Students’ Scientific Club, Department of Neurosurgery, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland https://orcid.org/0009-0001-0897-6855

DOI:

https://doi.org/10.31435/ijitss.2(50).2026.5238

Keywords:

Meningioma, NF2, TERT, Genetic Studies, Chromosomal Abnormalities

Abstract

Introduction: Contemporary neuro-oncology considers meningioma development to result from a complex interplay between genetic predisposition, endocrine status, and metabolic background. Such an integrated approach is essential for the development of early diagnostic strategies, identification of high-risk populations, and implementation of personalized therapeutic principles in neurosurgical practice. The aim of this review was to systematize the most recent literature data concerning the integrated analysis of factors contributing to meningioma development.

Methods: A comprehensive literature search was conducted using the PubMed and Google Scholar databases, focusing on peer-reviewed studies published between 2016 and 2025.The following keywords were used: meningioma, NF2, TERT, genetic studies, chromosomal abnormalities.

Conclusions: A review of the current scientific literature indicates that meningioma development is driven by the complex interaction of genetic, hormonal, metabolic, and exogenous factors. Key molecular drivers include mutations in NF2, TRAF7, KLF4, SMO, and TERT, as well as epigenetic alterations. Hormonal status and metabolic disturbances, particularly obesity, insulin resistance, and dyslipidemia, appear to modulate tumor growth dynamics and recurrence risk. Ionizing radiation represents a major exogenous trigger of tumorigenesis. Further interdisciplinary research is required to improve understanding of meningioma pathogenesis and to facilitate the implementation of advanced diagnostic and therapeutic strategies.

References

Bance, S., & Shuaib, W. (2025). Meningioma. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK560538/

Brenner, A. V., Sugiyama, H., Preston, D. L., Sakata, R., French, B., Sadakane, A., Cahoon, E. K., Utada, M., Mabuchi, K., & Ozasa, K. (2020). Radiation risk of central nervous system tumors in the Life Span Study of atomic bomb survivors, 1958–2009. European Journal of Epidemiology, 35(6), 591–600. https://doi.org/10.1007/s10654-019-00599-y

Candelaria, P. V., Rampoldi, A., Harbuzariu, A., & Gonzalez-Perez, R. (2017). Leptin signaling and cancer chemoresistance: Perspectives. World Journal of Clinical Oncology, 8(2), 106–119. https://doi.org/10.5306/wjco.v8.i2.106

Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020). Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discovery, 10(8), 1103–1120. https://doi.org/10.1158/2159-8290.CD-19-1220

Clark, V. E., Erson-Omay, E. Z., Serin, A., Yin, J., Cotney, J., Ozduman, K., & Sestan, N. (2016). Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nature Genetics, 48(10), 1253–1259. https://doi.org/10.1038/ng.3651

Claus, E. B., Walsh, K. M., Calvocoressi, L., Bondy, M. L., Schildkraut, J. M., Wrensch, M., & Wiemels, J. L. (2022). Family history of cancer and risk of meningioma: Updated analysis. Cancer Epidemiology, Biomarkers & Prevention, 31(5), 1040–1046. https://doi.org/10.1158/1055-9965.EPI-21-1234

Driver, J., Hoffman, S. E., Tanloetkonok, W., Guzman, M. A., Polley, M. Y. C., Magill, S. T., Tihan, T., Theodosopoulos, P. V., McDermott, M. W., Gunter, N. L., Perry, A., Villanueva-Meyer, J. E., Raleigh, D. R., Brastianos, P. K., & Santagata, S. (2022). A molecularly integrated grade for meningioma. Neuro-Oncology, 24(5), 796–808. https://doi.org/10.1093/neuonc/noab213

Evans, D. G., Halliday, D., Obholzer, R., Afridi, S., Forde, C., Rutherford, S. A., Hammerbeck-Ward, C., Lloyd, S. K., Freeman, S. M., Pathmanaban, O. N., Thomas, O. M., Laitt, R. D., Stivaros, S., Kilday, J.-P., Vassallo, G., McBain, C., Lavin, T., Paterson, C., Whitfield, G., … King, A. T. (2020). Cancer and CNS tumor predisposition syndromes. Neuro-Oncology, 22(12), 1826–1843. https://doi.org/10.1093/neuonc/noaa109

Goldbrunner, R., Stavrou, I., Jenkinson, M. D., Sahm, F., Mawrin, C., Weber, D. C., Preusser, M., Santarius, T., Lefranc, F., Lund-Johansen, M., Tonn, J. C., McFaline-Figueroa, J. R., Brastianos, P. K., Shih, H. A., Kessler, U., Kanter, A. S., Galldiks, N., Kocher, M., Langen, K. J., & Weller, M. (2021). EANO meningioma guideline. Lancet Oncology, 22(9), e281–e292. https://doi.org/10.1016/S1470-2045(21)00017-3

Hall, E. J., & Giaccia, A. J. (2018). Radiobiology for the radiologist (8th ed.). Wolters Kluwer.

Hielscher, T., Sill, M., Sicking, S., Spohn, M., Schrimpf, D., Stichel, D., Sievers, P., Reuss, D. E., Kessler, T., Wick, W., Mawrin, C., Hartmann, C., Paulus, W., Herold-Mende, C., Tonn, J. C., Goldbrunner, R., Unterberg, A., von Deimling, A., & Sahm, F. (2023). Clinical implementation of integrated molecular-morphologic risk prediction for meningioma. Brain Pathology, 33(3), Article e13132. https://doi.org/10.1111/bpa.13132

Iyengar, N. M., Gucalp, A., Dannenberg, A. J., & Hudis, C. A. (2016). Obesity and cancer mechanisms: Tumor microenvironment and inflammation. Journal of Clinical Oncology, 34(35), 4270–4276. https://doi.org/10.1200/JCO.2016.67.4283

Jeggo, P. A., Pearl, L. H., & Carr, A. M. (2016). DNA repair and genome stability. Nature Reviews Molecular Cell Biology, 17(10), 657–670. https://doi.org/10.1038/nrm.2016.48

Kim, H., Cho, Y. H., Kim, J. H., Kim, C. J., & Roh, S. W. (2025). Radiation-induced meningiomas have an aggressive clinical course and a high prevalence of H3K27me3 loss. Journal of Korean Medical Science, 40(3), Article e62. https://doi.org/10.3346/jkms.2025.40.e62

Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Halfen, N., Guha, N., Baan, R., Wheeler, D., El Ghissassi, F., Bouvard, V., Straif, K., Cavalcante, A., de Camargo, B., Espina, C., Goodwin, P., Gruer, L., Handy, B., Heyworth, J., Juul, A., … Tsugane, S. (2016). Body fatness and cancer risk: Viewpoint of the IARC Working Group. New England Journal of Medicine, 375(8), 794–798. https://doi.org/10.1056/NEJMoa1511939

Malueka, R. G., Hartanto, R. A., Setyawan, N. H., Shofiyah, S., Adityatama, A., Wicaksono, A. S., Syafira, N., Hutami, H., Wardhani, I. C., Dananjoyo, K., & Bayuangga, H. F. (2022). Association of hormonal contraception with meningioma location in Indonesian patients. Asian Pacific Journal of Cancer Prevention, 23(4), 1047–1051. https://doi.org/10.31557/APJCP.2022.23.4.1047

Mei, Y., Bi, W. L., Greenwald, N. F., Du, Z., Agar, N. Y. R., Kaiser, U. B., Woodmansee, W. W., Reardon, D. A., Freeman, G. J., Wen, P. Y., & Santagata, S. (2017). Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. Cell Communication and Signaling, 15(1), Article 34. https://doi.org/10.1186/s12964-017-0189-7

Nassiri, F., Liu, J., Mansouri, S., Nejad, R., Zuccato, J. A., Karimi, S., Singh, O., Diamandis, P., Al-Omair, A., Mamatjan, Y., Suppiah, S., Farooq, H., Jalali, S., Wu, X., Patil, V., Singh, S., Wang, J. Z., Shrestha, S., Yao, Y., … Zadeh, G. (2021). A clinically applicable integrative molecular classification of meningiomas. Nature, 597(7874), 119–125. https://doi.org/10.1038/s41586-021-03850-3

Ostrom, Q. T., Price, M., Neff, C., Cioffi, G., Waite, K. A., Kruchko, C., & Barnholtz-Sloan, J. S. (2023). CBTRUS statistical report: Primary brain and other CNS tumors diagnosed in the United States in 2016–2020. Neuro-Oncology, 25(Suppl. 4), iv1–iv99. https://doi.org/10.1093/neuonc/noad149

Paramasivam, N., Hubschmann, D., Toprak, U. H., Ishaque, N., Neidert, M. C., Schrimpf, D., Stichel, D., Reuss, D. E., Sievers, P., Reinhardt, A., Wefers, A. K., Jones, D. T. W., Gu, Z., Aronica, E., Wick, W., Herold-Mende, C., von Deimling, A., Korshunov, A., & Sahm, F. (2019). Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathologica, 138(2), 295–308. https://doi.org/10.1007/s00401-019-02008-w

Pawloski, J. A., Fadel, H. A., Huang, Y. W., & Lee, I. Y. (2021). Genomic biomarkers of meningioma: A focused review. International Journal of Molecular Sciences, 22(19), Article 10222. https://doi.org/10.3390/ijms221910222

Portet, S., Banor, T., Bousquet, J., Roche, S., Boetto, J., Labrousse, F., Maurage, C. A., Gauchotte, G., Rigau, V., & Duffau, H. (2020). New insights into expression of hormonal receptors by meningiomas. World Neurosurgery, 140, e87–e96. https://doi.org/10.1016/j.wneu.2020.04.132

Preusser, M., Brastianos, P. K., & Mawrin, C. (2018). Advances in meningioma genetics: Novel therapeutic opportunities. Nature Reviews Neurology, 14(2), 106–115. https://doi.org/10.1038/nrneurol.2017.168

Raheja, A., & Satyarthee, G. (2017). Sphenoid wing en plaque meningioma development following craniopharyngioma surgery and radiotherapy. Asian Journal of Neurosurgery, 12(3), 358–361. https://doi.org/10.4103/1793-5482.180946

Rajaraman, P., Berrington de Gonzalez, A., Bouville, A., Chen, J. S., Cook, M. B., Doody, M. M., Hauptmann, M., Hoffman, D. A., Inskip, P. D., Kitahara, C. M., Kleinerman, R. A., Linet, M. S., Lubin, J. H., Mabuchi, K., Ron, E., Schneider, A. B., Schubauer-Berigan, M. K., Sigurdson, A. J., & Silver, S. R. (2021). Ionizing radiation and risk of central nervous system tumors: Current evidence and future directions. Neuro-Oncology, 23(7), 1053–1064. https://doi.org/10.1093/neuonc/noaa246

Roland, N., Neumann, A., Hoisnard, L., Duranteau, L., Froelich, S., Zureik, M., & Weill, A. (2024). Use of progestogens and the risk of intracranial meningioma: National case-control study. BMJ, 384, Article e078078. https://doi.org/10.1136/bmj-2023-078078

Sánchez-Jiménez, F., Pérez-Pérez, A., de la Cruz-Merino, L., & Sánchez-Margalet, V. (2019). Obesity and breast cancer: Role of leptin. Frontiers in Oncology, 9, Article 596. https://doi.org/10.3389/fonc.2019.00596

Shu, X., Jiang, Y., Wen, T., Lu, S., Huang, H., Guo, L., & Li, M. (2019). Association of hormone replacement therapy with increased risk of meningioma in women. Asia-Pacific Journal of Clinical Oncology, 15(5), e147–e153. https://doi.org/10.1111/ajco.13121

Smith, M. J., Wallace, A. J., Bennett, C., Hasselblatt, M., & Evans, D. G. (2020). Germline SMARCB1 mutations and familial meningioma predisposition. Journal of Medical Genetics, 57(11), 757–764. https://doi.org/10.1136/jmedgenet-2019-106596

Smith, M. J., O’Sullivan, J., Bhaskar, S. S., Hadfield, K. D., Poke, G., Caird, J., Sharif, S., Eccles, D., Fitzpatrick, D., Rawluk, D., & Evans, D. G. (2021). Loss-of-function variants in SUFU cause familial multiple meningioma. Neuro-Oncology, 23(8), 1363–1373. https://doi.org/10.1093/neuonc/noab049

Takahashi, H., Sano, M., Furuya, N., Takebayashi, K., & Takamura, H. (2019). Mendelian randomization provides support for obesity as a risk factor for meningioma. Scientific Reports, 9, Article 309. https://doi.org/10.1038/s41598-018-36186-6

Voormolen, E. H. J., van der Heide, G. S., Versteeg, A., Swaans-van Heumen, I. G. M., & Teunissen-van Roessel, I. J. M. (2021). Intracranial meningiomas decrease in volume after discontinuing progestin. Neurosurgery, 89(2), 308–314. https://doi.org/10.1093/neuros/nyab164

Weill, A., Nguyen, P., Labidi, M., Vialard, J., Coste, J., Dray-Spira, R., Zureik, M., & Froelich, S. (2021). Use of high-dose cyproterone acetate and risk of intracranial meningioma in women. BMJ, 372, Article n37. https://doi.org/10.1136/bmj.n37

Weller, M., Roth, P., Sahm, F., Capper, D., Genbrugge, E., & Wick, W. (2017). Durable control of metastatic AKT1-mutant WHO grade I meningioma by the AKT inhibitor AZD5363. Journal of the National Cancer Institute, 109(3), Article djw320. https://doi.org/10.1093/jnci/djw320

Yamanaka, R., Hayano, A., & Kanayama, T. (2017). Radiation-induced meningiomas: An exhaustive review of the literature. World Neurosurgery, 97, 635–644.e8. https://doi.org/10.1016/j.wneu.2016.09.094

Zotti, T., Scudiero, I., Vito, P., & Stilo, R. (2017). The emerging role of TRAF7 in tumor development. Journal of Cellular Physiology, 232(6), 1233–1238. https://doi.org/10.1002/jcp.25676